ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)

Clinical trial NCT04916613 · RECRUITING

Trial details

NCT number: NCT04916613
Sponsor: UNICANCER
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Prostate Cancer Metastatic

Start date: 2022-04-19
Primary completion: 2028-03-01
Enrollment: 300

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.